Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.850
-0.010 (-0.54%)
At close: Apr 28, 2026, 4:00 PM EDT
1.880
+0.030 (1.62%)
After-hours: Apr 28, 2026, 7:36 PM EDT
Milestone Pharmaceuticals Revenue
In the year 2025, Milestone Pharmaceuticals had annual revenue of $1.55M. Milestone Pharmaceuticals had revenue of $1.55M in the quarter ending December 31, 2025.
Revenue (ttm)
$1.55M
Revenue Growth
n/a
P/S Ratio
146.77
Revenue / Employee
$40,684
Employees
38
Market Cap
226.90M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Heron Therapeutics | 154.90M |
| Codexis | 70.39M |
| Fennec Pharmaceuticals | 44.64M |
| Voyager Therapeutics | 40.37M |
| Orchestra BioMed Holdings | 33.48M |
| Adagene | 7.67M |
| Camp4 Therapeutics | 3.50M |
MIST News
- 15 days ago - Milestone Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 18 days ago - Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT - GlobeNewsWire
- 21 days ago - Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 26 days ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - GlobeNewsWire
- 5 weeks ago - Why Milestone Pharma Stock Is Taking A Dive Today - Benzinga
- 5 weeks ago - Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - GlobeNewsWire